Compassionate Use of Certolizumab Pegol in Patients with Crohn's Disease Who Have Failed Previous TNF Inhibitor Therapies

被引：0
|
作者：
Vermeire, Severine [1 ]
Howaldt, Stefanie
Hommes, Daan [2 ]
Bressler, Brian [3 ]
Colombel, Jean-Frederic [4 ]
Mitchev, Krassimir [5 ]
Rutgeerts, Paul [1 ]
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Leiden Univ, Leiden, Netherlands
[3] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
[4] Hop Claude Huriez, Lille, France
[5] UCB, Briane Lalleud, Belgium
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2010年 / 105卷
关键词：
D O I：
10.14309/00000434-201010001-01149
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1149
引用
收藏
页码：S416 / S416
页数：1
相关论文
共 50 条
  • [31] Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients who are primary non-responders or intolerant to infliximab:: A real life multi-center experience of compassionate use
    Danese, Silvio
    Mocciaro, Filippo
    Guidi, Luisa
    Scribano, Maria Lia
    Comberlato, Michele
    Vangeli, Marcello
    Pulitano, Raffaella
    Manca, Aldo
    Armuzzi, Alessandro
    Malesci, Alberto
    Prantera, Cosimo
    Cottone, Mario
    GASTROENTEROLOGY, 2008, 134 (04) : A663 - A663
  • [32] Long-term remission with certolizumab pegol in Crohn's disease: Efficacy over 4.5 years in patients with no prior TNF inhibitor exposure (PRECiSE 3 study).
    Lichtenstein, G.
    Thomsen, O.
    Schreiber, S.
    Lawrance, I
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S51 - S52
  • [33] Certolizumab pegol improves HRQoL in patients with Crohn's disease: Data from PRECiSE 2
    Feagan, B.
    Keininger, D.
    Coteur, G.
    Schreiber, S.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (05) : 661 - 662
  • [34] Patients With Crohn's Disease Treated With Certolizumab Pegol Experienced Long-Term Remission Regardless of Prior TNF-α Inhibitor Exposure (PRECiSE 4 Study)
    Sandborn, William J.
    Schreiber, Stefan
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Lichtenstein, Gary
    GASTROENTEROLOGY, 2010, 138 (05) : S9 - S9
  • [35] Antibodies to infliximab in patients with Crohn's disease do not cross-react with certolizumab pegol
    Vetterlein, O.
    Kopotsha, T. M.
    Nesbitt, A. M.
    Brown, D. T.
    Stephens, S.
    GUT, 2007, 56 : A116 - A116
  • [36] Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
    Colombel, Jean-Frederic
    Sandborn, William J.
    Allez, Matthieu
    Dupas, Jean-Louis
    Dewit, Olivier
    D'Haens, Geert
    Bouhnik, Yoram
    Parker, Gerald
    Pierre-Louis, Bosny
    Hebuterne, Xavier
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (03) : 423 - +
  • [37] Response to certolizumab pegol induction is not steroid-dependent in patients with active Crohn's disease
    Hommes, Daniel W.
    GASTROENTEROLOGY, 2008, 134 (04) : A494 - A494
  • [38] Long-term Remission with Certolizumab Pegol in Crohn's Disease: Efficacy Over 4.5 Years in Patients with No Prior TNF Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole
    Schreiber, Stefan
    Lawrance, Ian
    Hanauer, Stephen
    Bloomfield, Ralph
    Sandborn, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S417 - S418
  • [39] Certolizumab pegol -: Treatment of rheumatoid arthritis, treatment of Crohn's disease, human anti-TNF-α monoclonal antibody
    Sorbera, LA
    Leeson, PA
    DRUGS OF THE FUTURE, 2005, 30 (11) : 1087 - 1091
  • [40] Benefit-risk assessment of the TNF-antagonists adalimumab and certolizumab pegol for maintenance treatment of Crohn's disease
    Colombel, Jean-Frederic
    Panaccione, Remo
    Robinson, Anne
    Thakkar, Roopal
    Huang, Bidan
    Pollack, Paul
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S22 - S23
12345